Introduction {#s1}
============

In human, cholesterol is transported by lipoproteins \[i.e., low-density lipoproteins (LDL) and high-density lipoproteins (HDL)\], which permit its transfer to tissues. Cholesterol elimination from the body is performed via the reverse cholesterol transport pathway, which allows the transfer of peripheral cholesterol to HDL and eventually its transfer to the liver for excretion. Interestingly, solid tumors have been shown to accumulate greater amounts of cholesterol when compared to the host healthy tissues (Freeman and Solomon, [@B27]; Krycer and Brown, [@B45]; de Gonzalo-Calvo et al., [@B19]). Intratumor accumulation of cholesterol appears to be a consequence of both *de novo* synthesis and lipoprotein-mediated uptake (de Gonzalo-Calvo et al., [@B19]; Murai, [@B59]). In this mini-review, we will focus on the role of the HDL receptor, the scavenger receptor class B type I (SR-BI) in the regulation of cholesterol and lipoprotein metabolism in the context of cancer. Although SR-BI\'s contributions to reverse cholesterol transport in cardiovascular diseases have been extensively studied, recent evidence has suggested that cholesterol and its metabolites may play a critical role in cancer progression (Danilo and Frank, [@B17]; Silvente-Poirot and Poirot, [@B77]; Simko and Ginter, [@B80]; Kuzu et al., [@B46]).

SR-BI: initial characterizations {#s2}
================================

SR-BI is a member of the Class B family of Scavenger Receptor proteins, which also include CD36 Antigen-like2 (LIMPII) and CD36 (Calvo et al., [@B6]). These three glycoproteins share a common structure: two transmembrane domains associated with two intracellular N- and C-termini and an extracellular glycosylated central domain. Initially, human SR-BI was termed CD36 and LIMPII Analogous-1 (CLA-1; Calvo and Vega, [@B8]) and was found to be highly expressed in adrenal glands (Liu et al., [@B51]), liver and steroidogenic tissues (Calvo et al., [@B7]). SR-BI is a receptor for HDL, and it promotes selective HDL-cholesteryl ester (HDL-CE) uptake by cells without particle uptake (Silver et al., [@B79]; Trigatti et al., [@B89]). Additionally, studies have shown that SR-BI can also promote the elimination of excess body cholesterol via billiary cholesterol secretion (Harder et al., [@B33]; Wiersma et al., [@B97],[@B96]).

*SCARB1* gene localization, splice variants, and protein domains {#s3}
================================================================

The gene encoding SR-BI has been designated *SCARB1*. Human *SCARB1* is located on chromosome 12 at q24.31 and comprises 13 exons and 12 introns that span over 86 kb. Due to alternative splicing sites, several mRNA variants of *SCARB1* have been identified (Webb et al., [@B95], [@B94]). Interestingly, a short variant containing only the last 2 exons of *SCARB1* has been detected by next-generation sequencing in non-malignant adrenal glands and livers at relatively high levels (Carithers et al., [@B12]). Nevertheless, no experimental data has been reported on the physiological significance of this finding.

The predicted molecular weight of SR-BI is 56.9 kDa, but it is frequently detected as an 82 kDa protein after SDS-PAGE migration due to post-translational glycosylation (Acton et al., [@B1]; Babitt et al., [@B5]). Using SR-BI aminoacid sequence Q8WTV0-2 (UniProt, [@B92]), the following main domains of SR-BI can be identified: Cytoplasmic N-terminal domain (residues 1--11), transmembrane domain \#1 (residues 12--32), extracellular domain (residues 33--440), transmembrane domain \#2 (residues 441--461), and cytoplasmic C-terminal domain (residues 462--509). According to the UniProt website (accessed July 2016, UniProt, [@B92]), five protein variants may be produced by alternative splicing of human *SCARB1* mRNA: isoform 3 (Q8WTV0-1), the canonical sequence, represents the longest variant with 552 residues; isoform 1 (Q8WTV0-2), the first isoform identified and named SR-BI, with 509 residues; isoform 2 (Q8WTV0-3; aka, SR-BII), with 409 residues; isoform 4 (Q8WTV0-2; aka, SR-BIII), with 474 residues; and isoform 5 (Q8WTV0-5), with 506 residues. Isoforms 1, 2, and 4 share a common C-terminal sequence (468--552 aa) that includes the VLQEAKL sequence required to bind the PDZ domain-containing protein (PDZK1), which has also been described in the mouse sequence (Silver, [@B78]; Kocher et al., [@B43]). The physiological relevance of these variants is not evident but SR-BII has been shown to display reduced selective cholesteryl ester uptake efficiency from HDL (Webb et al., [@B94]). SR-BI isoform distribution may also be altered in certain types of cancer (Arenas et al., [@B2]), compared to the corresponding healthy tissues, and it is possible that different SR-BI isoforms may have different ability to promote cholesterol entry or efflux. Therefore, these isoforms may differently regulate cholesterol homeostasis and/or signaling pathways involved in tumor progression.

Regulations of *SCARB1* transcription and SR-BI protein levels {#s4}
==============================================================

Steroidogenic tissues (Cao et al., [@B10]; Azhar et al., [@B4]) and the liver (Malerød et al., [@B54]; Huby et al., [@B37]) present the highest levels of *SCARB1* transcript. Accordingly, a strong control over transcription of this gene has been recognized. mRNA transcription of *SCARB1* is finely regulated in cells that perform steroidogenesis, such as the ovaries (Li et al., [@B49]) and adrenal glands (Imachi et al., [@B38]). It has been shown that the adrenocorticotropic hormone (ACTH), via cAMP, can stimulate SR-BI expression in human adrenocortical cell lines and promotes the secretion of aldosterone and cortisol (Imachi et al., [@B38]). However, no canonical cAMP responsive element (CRE) has been found in the promoter of *SCARB1* (Towns and Menon, [@B87]). This finding suggests that activation via CREB may occur via non-canonical CRE elements or cAMP regulates the activity of other transcription factors. Several activators of *SCARB1* transcription have been identified in a variety of cell types. Activation by Peroxisome proliferator-activated receptors (PPARα and PPARγ) promotes transcription of *SCARB1* in monocytes and macrophages (Chinetti et al., [@B15]). Similarly, activation of the Mek1/2/PPARα pathway has been demonstrated to up-regulate SR-BI (Wood et al., [@B98]). SREBP-2, which is a key regulator of cholesterol metabolism, binds *SCARB1* promoter to induce *SCARB1* mRNA up-regulation (Tréguier et al., [@B88]). LXRα/RXR and LXRβ/RXR have also been shown to induce *SCARB1* transcription in human and murine hepatoma cell lines and in 3T3-L1 preadipocytes independently of SREBP-1 (Malerød et al., [@B54]). In agreement with these findings, the LXR agonist T0901317 but not 22-(R)-hydroxycholesterol has been shown to induce an up-regulation of *SCARB1* mRNA in endothelial cells (Norata et al., [@B63]). Finally, 17β-estradiol has also been shown to transcriptionally up-regulate SR-BI via PKC activation in vascular endothelial cells (Fukata et al., [@B29]). Taken together, these data show that regulation of *SCARB1* transcription is strongly controlled by signaling pathways involved in cellular lipid/cholesterol homestasis. Therefore, it is not surprising to observe an upregulation of SR-BI in cancer cells (Table [1](#T1){ref-type="table"}), which often display increased cellular cholesterol levels.

###### 

**Expression of SR-BI in cancer tissues or cell lines and its association with malignant features**.

  **Type of cancer**          **Type of sample**   **Expression levels (compared to non-malignant tissue or cells)**   **Associated with**                                                               **References**
  --------------------------- -------------------- ------------------------------------------------------------------- --------------------------------------------------------------------------------- ----------------------------
  Adrenocortical carcinomas   Tissue               Decreased                                                           ND                                                                                Liu et al., [@B51]
  Testicular seminoma         Tissue               Decreased                                                           ND                                                                                Arenas et al., [@B2]
  Leydig cell tumor           Tissue               Increased                                                           ND                                                                                Liu et al., [@B51]
  Breast                      Tissue               Increased                                                           ND                                                                                Cao et al., [@B11]
  Breast                      Tissue               Increased                                                           More aggressive tumor type                                                        Yuan et al., [@B102]
  Prostate                    Tissue               Increased                                                           Increased malignancy and androgen-independent growth                              Schorghofer et al., [@B73]
  Nasopharyngeal carcinoma    Tissue               Increased                                                           ND                                                                                Zheng et al., [@B104]
  Nasopharyngeal carcinoma    Cell line            Increased                                                           Enhanced cell migration but not proliferation                                     Zheng et al., [@B104]
  Breast                      Cell line            NA                                                                  Enhanced proliferation                                                            Cao et al., [@B11]
  Breast                      Cell line            NA                                                                  Enhanced proliferation and migration, and tumor growth in xenograft tumor model   Danilo et al., [@B18]
  Prostate                    Cell line            NA                                                                  PSA production and cell viability                                                 Twiddy et al., [@B91]
  Breast                      PyMTTg mouse model   Increased                                                           Tumor growth                                                                      Llaverias et al., [@B52]
  Prostate                    TRAMP mouse model    Increased                                                           Tumor growth                                                                      Llaverias et al., [@B53]

ND, not determined; NA, not applicable.

Furthermore, recent studies have also shown that the proto-oncogene c-Myc may play a role in the regulation of *SCARB1* transcription (Pello et al., [@B65]). Moreover, *in silico* nucleotide analysis of *SCARB1* promoter (nucleotide −499 to 100, LASAGNA Search 2.0) shows potential binding sites for c-Myc, Stat proteins, PPARγ, p53, and NF-κB. Given the role of transcription factors such as c-Myc, p53, Stat in cancer, additional studies should be designed to better understand the role of these transcription factors in the regulation of SR-BI expression in cancer.

In addition to transcription factors regulating gene expression, mRNA levels of *SCARB1* can also be regulated by microRNAs (miRNAs), which can bind the 3′-UTR of mRNA. Studies have shown that miR-125a and miR-455 can reduce both mRNA and protein levels of SR-BI in steroidogenic cells (Hu et al., [@B36]). Similarly, miR-185, -96, and -223 have been shown to decrease mRNA levels of *SCARB1* in HepG2 cells (Wang et al., [@B93]). Finally, miR-192 was found to directly target *SCARB1* mRNA in adipocytes (Mysore et al., [@B60]). Although no data on the role of these miRNAs in the context of *SCARB1* and cancer is available, recent studies have shown that levels of miR-125a (Guo et al., [@B32]; He et al., [@B35]; Tong et al., [@B86]; Lee et al., [@B47]), miR-455 (Chai et al., [@B13]; Li et al., [@B50]), miR-185 (Qu et al., [@B69]; Fu et al., [@B28]; Tang et al., [@B83]; Li et al., [@B48]; Zhang et al., [@B103]), and miR-192 (Feng et al., [@B23]; Geng et al., [@B31]; Sun et al., [@B82]) are down-regulated in several types of cancer. These findings suggest that *SCARB1* post-transcriptional regulation may be altered to promote SR-BI expression in cancer cells.

A post-translational regulation of SR-BI has also been described. In this case, PDZK1 has been shown to physically interact with SR-BI via a 7-residue domain present in the C-terminal domain (Silver, [@B78]; Kocher et al., [@B43]). This interaction was demonstrated to be essential for SR-BI post-transcriptional stabilization in a tissue-dependent manner (Kocher et al., [@B44]) and localization to the plasma membrane of hepatocytes (Silver, [@B78]; Kocher et al., [@B44]) but not relevant for its selective HDL-CE uptake function (Silver, [@B78]). Importantly, phosphorylation of serine 509 of PDZK1 is crucial for SR-BI stabilization (Nakamura et al., [@B61]). Despite these findings, the role of PDZK1 in SR-BI post-translational regulation does not appear to be required in all cell types. In fact, absence of PDZK1 does not affect SR-BI levels in murine steroidogenic tissues (Kocher et al., [@B44]) and human endothelial cells (Kimura et al., [@B41]). Remarkably, recent studies have demonstrated that PDZK1 expression is correlated with Akt activation in the MCF-7 breast cancer cell line (Kim et al., [@B40]). This observation implies a positive feedback regulation between PI3K/AKT and SR-BI since PI3K is activated by SR-BI (Kimura et al., [@B41]). Alternatively, SR-BI protein levels may be regulated by Mek1/2, which prevents SR-BI proteosomal degradation in hepatocytes (Wood et al., [@B98]). Taken together, these studies highlight the complex regulation of *SCARB1*/SR-BI transcription/expression levels.

Signaling pathways regulated by SR-BI and HDL {#s5}
=============================================

Few data are currently available concerning the signaling pathways activated or repressed by SR-BI in cancer cells. We have previously reported that HDL/SR-BI interaction can activate both PI3K and Erk1/2 pathways in two breast cancer cell lines (Danilo et al., [@B18]). These findings are consistent with results obtained with endothelial cells (Kimura et al., [@B42]). Besides, SR-BI also interacts with PDZK1, and this interaction is required to mediate eNOS activation and endothelial cell migration. Interestingly, PDZK1 is not required for HDL binding, SR-BI plasma membrane localization, nor cholesteryl ester uptake (Zhu et al., [@B106]). It has been proposed that PDZK1 is important for HDL/SR-BI-mediated activation of the PI3K (Kimura et al., [@B41]) and c-Src (Zhu et al., [@B106]) pathways, and stimulation of migration in endothelial cells (Zhu et al., [@B106]; Figure [1](#F1){ref-type="fig"}). Importantly, activation of this signaling cascade has been shown to require the interaction of c-Src and SR-BI cytoplasmic C-terminal domain (Seetharam et al., [@B74]; Zhu et al., [@B106]).

![**Role of SR-BI in the regulation of cellular signaling pathways and regulation of its expression in cancer cells**. PPARα and/or PPARγ and SREBP pathways may be activated to promote *SCARB1* gene expression. In addition, as described in macrophages, high levels of glucose may also contribute to SR-BI up-regulation via pathways that remain to be identified. Several miRNAs (such as miR-192, -185, -125a, and -455) have been found to regulate the post-transcriptional expression of SR-BI. Interestingly, these miRs are down-regulated in several cancers. Once associated with the plasma membrane, SR-BI contributes to the uptake of cholesteryl ester (CE) from HDL. A relevant residue in SR-BI for this interaction is Cys384 (denoted with an orange label). CE may be converted into free cholesterol (FC) which can be incorporated in the plasma membrane or organelles (such as mitochondria), stored in lipid droplets (LD), or used as substrate for steroids and other cholesterol metabolites. The C-terminal domain of SR-BI (denoted in yellow) interacts with PDZK1, which can activate PI3-kinase (PI3K) and c-Src pathways to promote proliferation and migration. Another yet unexplored role of SR-BI is its interaction with apoptotic cells. This interaction may also contribute to the activation of signaling pathways that promote malignant features.](fphar-07-00338-g0001){#F1}

Signaling pathways activated by another member of the class B scavenger receptor, CD36, have also been investigated. The C-terminal domain of CD36 has been shown to also physically interact with Src family non-receptor tyrosine kinases (Moore et al., [@B58]; Rahaman et al., [@B70]; Tao et al., [@B84]) that activates a cascade of signaling molecules such as MAPK, p38, JNK, FAK, and GTPases (reviewed in Park, [@B64]). Conversely, over-expression of a mutant version of SR-BI (lacking the C-terminal residues 465 to 509) has been shown to prevent HDL-induced proliferation in the MCF-7 breast cancer cell line (Cao et al., [@B11]). Since MCF-7 endogenously express significant levels of SR-BI (Danilo et al., [@B18]), the later finding implies a competitive effect for the SR-BI mutant in binding HDL and regulating down-stream signaling pathways. Taken together, these data suggest a relevant role for the C-terminal domain of SR-BI in cell proliferation of breast cancer cells.

SR-BI, regulation of cellular cholesterol homeostasis and cancer {#s6}
================================================================

The role of cholesterol in tumor progression has been extensively studied in the past decade. Cholesterol has been shown to regulate essential signaling pathways involved in cellular proliferation, migration, survival, thereby promoting cancer progression. In that regard, several studies have shown that plasma membrane cholesterol plays an important role in these pathways (Zhuang et al., [@B107]). Furthermore, SR-BI has been shown to regulate cellular cholesterol homeostasis (Phillips, [@B67]). While CD36 localization in cholesterol-rich plasma membrane and interaction with caveolin-1 has clearly been established (Frank et al., [@B26]; Ring et al., [@B72]; Thorne et al., [@B85]), contradictory results have been obtained concerning SR-BI and its interaction with specific plasma membrane domains and cholesterol. Initial studies by Babitt et al. ([@B5]) have suggested that SR-BI colocalizes with caveolae and is fatty acylated in the CHO-ldla7-mSR-BI and Y1-BS1 cell lines. These findings were confirmed by us using COS-7 (Frank et al., [@B26]) but Rhainds et al. found SR-BI in lipid raft membrane domains devoid of caveolin-1 in HepG2 cells (Rhainds et al., [@B71]). However, other studies using WI38\[SR-BI\] and ACTH-treated murine adrenal Y1-BS1 cells showed that SR-BI was preferentially associated with non-detergent-resistant membranes and no interaction with caveolin-1 was needed to reach the plasma membrane (Peng et al., [@B66]). Specific culture conditions or cell types may explain some of the observed contradictory results. Nevertheless, the C-terminal transmembrane domain of SR-BI has been shown to interact with cholesterol, and this domain may act as a cholesterol-sensing domain, which function remains to be established (Assanasen et al., [@B3]). While we have shown that the downregulation of SR-BI in breast cancer cell lines is associated with reduced cellular cholesterol content and reduced tumor aggressivity (Danilo et al., [@B18]), it remains to be determined whether SR-BI-regulated signaling pathways and cholesterol homeostasis can be uncoupled.

Role of SR-BI in cancer {#s7}
=======================

Although no study examining the role for SR-BI in the promotion of cell transformation has been performed, it has been recognized that cancer cells can use the HDL/SR-BI pathway to take up cholesteryl ester and enhance malignant phenotypes (Figure [1](#F1){ref-type="fig"}; Danilo et al., [@B18]; Zheng et al., [@B104]). As shown in Table [1](#T1){ref-type="table"}, SR-BI expression is up-regulated in Leydig cell tumors, nasopharyngeal carcinoma, and breast and prostate cancers. Among these cancers, the role of HDL/SR-BI in breast and prostate cancers have been the most extensively studied. The breast cancer cell line HBL-100 can take up cholesteryl ester from apoE-depleted HDL~3~ via SR-BI (Pussinen et al., [@B68]). Additionally, over-expression of SR-BI can enhance HDL-mediated proliferation of the breast cancer cell line MCF-7 via the PI3K/AP-1 pathway (Cao et al., [@B11]). In further support of a role for HDL/SR-BI in breast cancer growth, we have also demonstrated that HDL/SR-BI interaction is required for breast cancer cells to proliferate and migrate *in vitro*, and SR-BI promotes the growth of tumors *in vivo* (Danilo et al., [@B18]). Similarly, proliferation of mesenchymal stem cells is also enhanced by HDL/SR-BI interaction where MAPK/ERK1/2 and PI3K/AKT pathways have been inplicated (Xu et al., [@B99]). Conversely, down-regulation of SR-BI in prostate cancer cells (C4-2 and LNCap cell lines) has been shown to cause a significant reduction in cellular viability and PSA secretion (Twiddy et al., [@B91]) and inhibit cellular motility in a wound-healing assay of nasopharyngeal cancer cell lines (Zheng et al., [@B104]). However, studies by Sekine et al. have shown that SR-BI did not regulate HDL-mediated proliferation of the PC-3 prostate cancer cell line (Sekine et al., [@B75]). Nevertheless, down-regulation of SR-BI has also been observed in adrenocortical carcinomas and testicular seminoma (Table [1](#T1){ref-type="table"}). The reasons for these differences are not clear but may involve different requirements for cholesterol uptake by the tumors. In the later cases, cholesterol levels may not be a rate-limiting factor for tumor growth. Alternatively, other isoforms of SR-BI or alternative cholesterol uptake pathways may be upregulated and allow the maintenance of a "tumor specific cholesterol homeostasis."

While SR-BI mediates HDL-CE uptake in hepatocytes, in peripheral tissues, SR-BI binding to HDL can stimulate a net exit of cholesterol via cholesterol efflux from intracellular stores. In cancer, efflux and influx might be finely regulated to ensure the maintenance of high levels of intracellular cholesterol within proliferative cancer cells. The direction of cholesterol flux may depend on the specific and respective properties of cholesterol acceptors and cellular plasma membrane. Cholesterol efflux mediated by SR-BI highly correlates with HDL phospholipid content present in serum (Fournier et al., [@B24], [@B25]). To further test the role of phospholipid, reconstituted HDL enriched with phosphatidylcholine or sphingomyelin have been used to study efflux and influx mediated by SR-BI in CHO cells (Yancey et al., [@B100]). It was concluded that sphyngomyelin-enriched HDL enhanced net efflux by decreasing SR-BI-mediated cholesterol influx, whereas phosphatidylcholine enrichment of HDL increased SR-BI-mediated efflux (Yancey et al., [@B100]). However, it is currently unknown if the same mechanisms can regulate cholesterol homeostasis in cancer cells.

When the concentration of glucose is abnormally elevated as in diabetes, cholesterol metabolism in macrophages is impaired (Hayek et al., [@B34]; Zhou et al., [@B105]). Interestingly, a glucose-concentration-dependent increase in SR-BI mRNA and protein levels has been proposed as an explanation for the abnormal cholesterol metabolism observed in macrophages and other cells (Tu and Albers, [@B90]). Moreover, elevated glucose concentrations can reduce HDL-mediated cholesterol efflux and increase total macrophage cholesterol levels (Gantman et al., [@B30]). Importantly, glucose uptake is remarkably enhanced in tumors (Cantor and Sabatini, [@B9]), and previous studies have demonstrated a pro-proliferative role of glucose in the regulation of cellular proliferation of cancer cells (Masur et al., [@B56]). Since glucose and lipid metabolism are interconnected (reviewed in (Dang, [@B16])), these findings suggest that tumor cell exposure to glucose may contribute in cancer cells to SR-BI upregulation that may participate in cancer progression (Figure [1](#F1){ref-type="fig"}). Interestingly, HDL has also been shown to regulate glucose metabolism in various cell types (Siebel et al., [@B76]).

Development of SR-BI inhibitors {#s8}
===============================

SR-BI effect on cholesterol transport has been extensively studied in cardiovascular diseases. Not surprisingly, pharmacological drugs that block SR-BI-mediated HDL-CE uptake have been developed in this particular context. Strategies have been applied to design new specific compounds to target SR-BI. Using high-throughput screening (HTS), BLT-1 (block lipid transport 1) was found to specifically inhibit SR-BI lipid transfer (Nieland et al., [@B62]). This inhibitor blocks entry of HDL-CE by targeting Cys384 in the extracellular domain of SR-BI (Yu et al., [@B101]). Importantly, our group has reported that BLT-1 can inhibit SR-BI-mediated cellular proliferation in breast cancer cells (Danilo et al., [@B18]). Another small molecule, ITX5061, has been shown to increase plasma HDL levels in wild type and human apoA-I transgenic mice in an SR-BI-dependent manner (Masson et al., [@B55]). Around a decade after BLT-1 discovery, new molecules (ML278, ML279, ML312) were identified by HTS as potent inhibitors with less deleterious effects than ITX5061 and BLT-1 (Faloon et al., [@B21],[@B20],[@B22]). More recently, using structural comparative analysis to ITX-5061, a non-absorbable potent compound inhibiting SR-BI has been identified (Sparks et al., [@B81]).

Antibodies against the extracellular domain of SR-BI have also been developed to prevent HDL binding. Accordingly, a neutralizing antibody against aminoacids 174--356 of murine SR-BI can block both HDL binding and selective cholesteryl ester uptake in murine macrophages (Chen et al., [@B14]). These new compounds should bring scientists new tools to investigate the role of SR-BI in cancer development and permit the identification of new strategies to inhibit tumor growth and cancer progression.

Recent works have also demonstrated that mimetics of HDL (a.k.a., nanoparticles) can target cells expressing SR-BI. In these cases, studies have shown that tumor cells overexpressing SR-BI could be targeted by nanocomplexes, which may promote the transfer of lipoprotein-derived cargo content (Zheng et al., [@B104]; McMahon et al., [@B57]; Julovi et al., [@B39]). While this approach appears to be efficient, it is important to note that SR-BI is also present at the surface of important non-tumor cells (e.g., hepatocytes, endothelial cells...). Therefore, targeting SR-BI at the surface of tumor cells will require the development of new methods allowing the specific targeting of these cell types.

Conclusions {#s9}
===========

Additional studies remain to be performed to better establish the role of SR-BI in cancer. In particular, the role of the different sub-populations of HDL and of other lipoproteins such as LDL needs to be better characterized. Moreover, it remains to be determined whether SR-BI can regulate concommitantly cellular cholesterol homeostasis and various cellular signaling pathways. Therefore, the development of new types of SR-BI inhibitors and the identification of their mechanism of action should provide new information. Alternatively, the use of SR-BI mutants and/or SR-BI/CD36 chimeric constructs should also allow us to better understand the role of SR-BI in cancer.
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